Streetbeat News

ALPN

Alpine Immune Sciences Inc

CEO

Mitchell Gold

Employees

125

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Analysts have recently evaluated Alpine Immune Sciences (NASDAQ:ALPN), with 11 analysts providing diverse outlooks. The average 12-month price target has increased by 42.11% to $54.0. Key analysts have raised their price targets, reflecting positive sentiment.

Portfolio Pulse from Benzinga Insights

May 16, 2024 | 1:00 pm

Wedbush analyst Robert Driscoll has reiterated a Neutral rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a $65 price target.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 12:38 pm

Alpine Immune Sciences (NASDAQ:ALPN) reported Q1 earnings with losses of $(0.28) per share, surpassing the $(0.41) estimate, and sales of $7.03M, exceeding the $3.52M estimate. Despite beating estimates, sales decreased by 25.09% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:25 pm

Vertex Pharmaceuticals Inc (VRTX) has seen significant success with its cystic fibrosis drug Trikafta, generating $26 billion in revenues since 2019 and expected to reach $10 billion in annual sales next year. The company is now focusing on developing non-opioid painkillers, with VX-548 in late-stage trials and potential FDA approval this year. Vertex also acquired Alpine Immune Sciences Inc (ALPN) for $4.9 billion to develop treatments for autoimmune kidney disease. Analysts predict Vertex's new pain medication could bring in $2.3 billion in annual sales by 2030.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:34 pm

TD Cowen analyst Boris Peaker downgraded Alpine Immune Sciences (NASDAQ:ALPN) from Buy to Hold, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 10:49 am

Leerink Partners analyst Thomas Smith downgraded Alpine Immune Sciences (ALPN) from Outperform to Market Perform while raising the price target from $42 to $65.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 1:54 pm

Vertex Pharmaceuticals Incorporated (VRTX) has agreed to acquire Alpine Immune Sciences Inc (ALPN) for approximately $4.9 billion in cash, at $65 per share. Analysts from Evercore, BofA, and William Blair have commented positively on the acquisition, highlighting the potential of Alpine's lead molecule, povetacicept (ALPN-303), and its alignment with Vertex's nephrology and cystic fibrosis pipelines. Evercore upgraded VRTX to Outperform with a $438 price target, while BofA maintains a Buy rating with a $550 price target. The acquisition is seen as a strategic move to bolster Vertex's clinical pipelines.

Portfolio Pulse from Vandana Singh

April 11, 2024 | 6:47 pm

Stocks rebounded with the Nasdaq 100 leading gains, up 1.2%, driven by Nvidia's 3.1% surge. The Producer Price Index (PPI) inflation was slightly lower than expected, affecting Fed rate cut expectations. Treasury yields were mixed, impacting the iShares 20+ Year Treasury Bond ETF (TLT), which fell 0.2%. Gold, tracked by the SPDR Gold Trust (GLD), rose nearly 1%, while Bitcoin softened. Notable stock movements included Nike's 3.8% rise after an upgrade, Paramount Global's 6.5% rally, and significant drops for Globe Life, CarMax, and Nikola Corp. Vertex Pharmaceuticals announced a $4.9 billion deal to buy Alpine Immune Sciences.

Portfolio Pulse from Piero Cingari

April 11, 2024 | 6:13 pm

Fastenal Company's shares dropped by around 7% due to disappointing Q1 FY24 financial results, with sales and EPS missing consensus estimates. Other stocks experienced significant movements, with Rallybio Corporation, Rent the Runway, and Eliem Therapeutics among the top gainers, while Aptevo Therapeutics, Enlivex Therapeutics, and AVITA Medical led the losers.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 5:33 pm

In Thursday's intraday session, several healthcare stocks experienced significant movements. Rallybio, Eliem Therapeutics, and Candel Therapeutics were among the top gainers, with shares increasing by 70.5%, 57.3%, and 40.58% respectively. Conversely, Aptevo Therapeutics, AVITA Medical, and BioSig Technologies were the leading losers, with their shares falling by 57.9%, 30.61%, and 25.35% respectively. These movements reflect notable volatility within the healthcare sector.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.